INTRODUCTION
The Wilson's disease (WD) gene has been mapped by linkage analysis to chromosome 13. The A possible diagnosis of WD should be considered in otherwise unexplained hepatic or neurological disease, especially in adolescents. Accurate diagnosis is important, since effective therapy of this otherwise fatal condition can be offered, but must be maintained for life. The presence of copper deposits in the eye (Kayser-Fleischer rings), increased copper in liver biopsy tissue (> 250pg of Cu/g dry weight), a decrease in total plasma copper ( < 5.0 pmol/l) and in plasma caeruloplasmin ( < 200 mg/l), an increased urine copper output ( > 2.0 pmo1/24 h), together with an appropriate clinical presentation, is usually suficient to make a diagnosis. However, patients may present with a suggestive history but equivocal biochemical findings. A variety of unrelated liver diseases in childhood result in copper accumulation with high liver copper content and Kayser-Fleischer -_ rings [TI.
Genetic classification by means of close-linked markers can be effective in-identifying asymptomatic cases and the carriers of the WD gene [6, 71. However, not all kindreds are informative due to the unavailability of key members of the family for study. Since there are multiple mutations within the WD gene, diagnosis using DNA from a suspected case is not yet feasible.
The incorporation of radioactive copper into plasma caeruloplasmin has been used in instances n a
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where the diagnosis was in doubt, and to attempt the identification of heterozygotes [S, 91. 64Cu has a short half-life (1 2 h), which makes organization of this test inconvenient and limited to specialized centres. Stable non-radioactive 65Cu avoids this disadvantage, also allowing studies in children and young women. Blood samples can be collected locally, stored and then sent to the laboratory for analysis. The incorporation of the isotope into the plasma pool and its subsequent removal by biliary excretion can be followed for periods of several weeks.
MATERIALS AND METHODS
The study was approved by the ethics committee of the Royal Infirmary, Glasgow. Control subjects were healthy laboratory staff ( < 50 years of age, six males and four females).
The WD cases (n= 13) and heterozygotes (n= 12) were recruited in the West of Scotland and from the Istituto di Medicina Interna, Universita di Padova, Padova, Italy. Two of the WD patients had received liver transplants, and four were receiving oral zinc 'blockade' therapy. Three siblings of WD cases were found to be normal. Five patients had other forms of liver disease. One patient was made available for study who had a genetic defect of caeruloplasmin synthesis. All patients and control subjects gave their informed consent.
Preparation of stable %u solution
The stable 65Cu isotope (99% enriched) (AEA Technology, Harwell, Oxon, U.K.) was obtained in the form of copper foil, which was dissolved in concentrated nitric acid (0.1 ml) and diluted with deionized water to give a solution with a concentration of 1mg of 65Cu/ml.
Oral uptake test protocol
Patients treated with penicillamine or trientene chelation therapy had this stopped at least 48 h before the test. Patients continued with their oral zinc therapy. After an overnight fast, an oral dose of 65Cu (3mg for an adult, 2mg for a child) was given after mixing the isotope solution in a glass of water or soft drink. Blood samples (10ml clotted) were taken at 1, 2, 6, 24, 48 and 72 h, and the serum was separated and stored (410°C). In six control subjects plus an additional four normal subjects, not otherwise reported here, blood sampling was continued at weekly intervals for up to 40days.
Preparation of samples for inductively coupled plasma: mass spectrometry (ICPMS)
The determination of the isotopic composition of copper in serum by ICPMS has been described by us elsewhere [lo] . For accurate measurement of the 65Cu/63Cu isotope ratio in serum, the sample must first be desalted, as Na+ ions give rise to the species 23Na40Ar+ (m/z 63) in the argon plasma of the mass spectrometer. Desalting was achieved by gel filtration. Serum (2.5 ml) was placed on a Pharmacia PD-10 column and eluted with deionized water (3.5 ml). The recovery of copper was 97 & 3.4%.
Sulphur causes an interference, at m/z 65, by formation of 32S1602H+, 32S'60170+ and 3 3 S ' 6 0 2 . + Sulphur in protein was removed by precipitation with concentrated nitric acid. Acid (200~1) was added to the 3.5ml column eluate, and the mixture was then centrifuged. Protein-bound copper was released into the supernatant acid solution, which was then diluted to lOml with water.
ICPMS analysis
The 65Cu/63Cu isotope ratio was determined in the lOml of dilute acid solution using a PlasmaQuad 1CP:MS (VG Elemental, Winsford, Cheshire, U.K.), housed at the Scottish Universities Research and Reactor Centre, East Kilbride, and at the Rowett Institute, Aberdeen, U.K., and the Istituto Superiore Di Sanita, Rome.
The spectra were corrected for background using a 4% nitric acid solution. The mass bias of the instrument was determined by running a natural copper standard (lOOpg/l) in replicate at the beginning, during and at the end of each day, and the measured ratios were corrected accordingly. The natural value of the 65Cu/63Cu ratio was taken to be 0.4474 [ll] . The precision of the ratio determination was less than 0.5%.
Rather than report the results as isotope ratios, it is convenient to report the percentage enrichment, which is defined as:
RESULTS

Normal response to an oral dose of &Cu
The results for the healthy control subjects are given in Table 1 (subject nos. 1-10). The average percentage enrichment time patterns, together with the upper and lower limits, are shown in Fig. 1 . The enrichment patterns for the control subjects all have the same general shape, and are comparable with the results found by others using the radioactive isotope 64Cu [9, 121. There is a peak value at 1-2 h, falling to a low at 6h, and then a secondary rise after about 3days. When expressed as ratios, the 72/ ,,-------.--_____ 2h ratio is greater than 0.5 and the 72/6h ratio is greater than 1.5 (Fig. 2) . The stable isotope allowed the fate of the oral dose of copper to be studied for longer than 64Cu (tllz = 12 h) would allow. The 65Cu percentage enrichment in ten control subjects followed from 3 to over 40days gave a mean biological half-time for copper in the plasma pool of 19.5+5days (meanfSD). The median was 18.5days, with an associated 95% confidence interval of 14-26 days ( Table 2) . 
Copper uptake pattern in WD
Homozygotes for the WD gene. WD patients previously treated with the chelating agents penicillamine or trientine have a pattern of tracer uptake markedly different from that of those treated by oral zinc therapy, who fail to absorb the Cu isotope to any significant extent ( Fig. 3 and Table 1 ).
The plasma protein 6'Cu enrichment in WD patients treated by chelation rises to a peak after 12 heterozygotes for the WD gene (Table 3) . These were either parents of known WD cases, or asymptomatic siblings in whom the genotype was established by us from DNA studies using four closely linked CA repeat markers, two on either side of the gene, as described by Thomas et al. [7] . With appropriate family members available, an unambiguous classification of 'heterozygote' or 'unaffected' can be assigned to healthy asymptomatic siblings. Inspection of the combined plots of the 72/2h and 7216 h 65Cu enrichment ratios showed that there was some separation of heterozygotes from control subjects, the heterozygotes mainly lying above the broken line (Fig. 2) . We can distinguish three types of response within the heterozygote population: (i) those with a definite secondary rise in 65Cu enrichment at 72 h (72:6 h ratio > lS), (ii) those with an impaired incorporation of 65Cu at 72 h (72:6 h ratio 1.0-1.5) and (iii) one example (no. 33) where there was a complete failure to incorporate 65Cu into the plasma protein pool (726h ratio << 1.0).
The biological half-time for clearance of 65Cu from the plasma pool was increased in the heterozygote group compared with control subjects. The eight heterozygotes that we were able to study for up to 40days had a median half-time for 65Cu in the plasma pool of 43days (95% confidence interval 32-77 days), which is significantly longer than the control group median of 18.5days (95% confidence interval 14-26 days) ( Table 2) . about 2 h and then decays rapidly towards the baseline. The secondary rise seen in control subjects is absent, indicating failure to incorporate 65Cu into plasma proteins (primarily caeruloplasmin). The percentage enrichment after 1-2h is high (median =47%, 95% confidence interval 25-1 18%) compared with the control subjects (median = lo%, 95% confidence interval 7.7-12.8%).
One case (no. 17) had only 5.4% enrichment at 2h, possibly due to the atypically high concentration of plasma copper at the time of isotope administration.
The percentage enrichment ratio for the seven WD cases at 7212h is 0.07rt0.06, and at 72/6h is 0.15 kO.06. Plotting the two percentage enrichment ratios (7212 and 72/6h) against each other clearly separates the control subjects and WD cases (Fig. 2) .
Two WD patients who had received liver transplants had a normal uptake of 65Cu. The 72/2h enrichment ratios were 1.5 and 1.8 (Fig. 2) .
Heterozygotes for the WD gene. We have studied &Cu uptake pattern in other diseases of the liver (Table 4) (i) A 9-year-old male child of Bangladeshi origin (no. 39), suffering from an 'idiopathic copper toxicity', had 18 months of treatment with penicillamine. The patient had presented with normal serum copper and caeruloplasmin, but elevated urine copper and an extremely high liver concentration of copper of 2319pgJg. The oral 65Cu (2mg) incorporation was assessed with blood samples taken at 2, 6 and 72h. There was a normal ability to incorporate the 65Cu into caeruloplasmin and WD could be excluded [13] .
(ii) A 9-year-old girl (no. 40) presented with jaundice and hepatosplenomegaly. She had an increased liver copper concentration at 838 pg/g and a somewhat increased urinary excretion of copper (1.2 pmollday). The 65Cu uptake pattern showed an enrichment maximum at 2 h, dropping by about half at 6h, but thereafter showed no secondary rise, remaining fairly constant up to 72 h. Although this is not a normal pattern, we consider that we can exclude WD, since the enrichment ratios were 721 2 h = 0.44 and 7216 h = 0.96.
(iii) An 11-year-old girl (no. 41) with ill-defined liver disease was thought to have chronic active hepatitis but exclusion of WD was thought necessary. She had an unusually high enrichment peak at 2 h which fell after 6 h and then remained constant (72/2 h = 0.69, 72/6 h = 1.1). These results exclude WD.
(iv) A 15-year-old boy (no. 42) with acute hepatitis had a high urine copper output after a penicillamine challenge. His incorporation of the 65Cu dose into caeruloplasmin was normal (72/2 h = 1.7, 72/ 6h=3.5) and W D could be excluded.
Caeruloplasrnin deficiency
A 58-year-old male patient (no. 43, Table 4) with the rare inborn error of acaeruloplasminaemia [ 141 was available for investigation. The 65Cu enrichment dropped from the 2 h maximum and decayed rapidly (72/2 h = 0.12), demonstrating a failure of W u incorporation into the plasma protein pool as a result of the lack of caeruloplasmin.
DISCUSSION
Results for W D patients, W D heterozygotes and for patients with hepatic disease are shown in Fig. 2, where the 65Cu percentage enrichment ratios at 72/2 h and 72/6 h are plotted. The group with other hepatic disorders is distinct from the W D cases. In patients with an atypical clinical presentation and equivocal copper biochemistry, W D can be excluded if the 72/2h 65Cu enrichment ratio is greater than 0.4.
Intestinal blockade of copper absorption in WD, using zinc salts given orally, has been assessed by measuring the oral absorption of 64Cu radioactive isotope before and after treatment [ 121. Equivalent information can be obtained with 65Cu, and we have shown in four patients treated with oral zinc that the average enrichment at 2 h (median=3.2%, 95% confidence interval 1.7-8.6%) is much lower than that observed in other W D patients being treated with chelating agents (median = 47%, 95% confidence interval 25-1 18%).
Known heterozygotes for the W D gene show varying degrees of impairment of 65Cu incorporation but are not wholly separated from control subjects (Fig. 2) .
One of the group (no. 33) was a biochemically abnormal heterozygote. This young asymptomatic woman was the sister of a patient with established WD who had required liver transplantation. She had many of the biochemical features of WD, with a low plasma copper concentration, low plasma caeruloplasmin concentration and raised liver copper concentration. Her 65Cu uptake test showed little incorporation of the isotope and was similar to established WD cases. However, her baseline urine copper output was normal, and she did not have a large increase in urinary copper after penicillamine. Using closely linked CA repeat markers, this girl was shown to be genetically different from her sister (no. 22). She has inherited the alternative allele from her mother, and therefore has one normal gene able to encode for the WD gene product. The allele that both girls have inherited from their father carries the mutant gene. The prescription of lifelong penicillamine chelation therapy in heterozygotes for the WD gene who have significant biochemical abnormalities of copper metabolism, but are clinically asymptomatic, is a matter of debate in view of the possible long-term effects.
The biological half-time of copper in plasma for control subjects was found to be 19.5f5days (mean f SD). This is considerably longer than the known half-time of 6.1 days for caeruloplasmin [l 51.
The half-time of copper in plasma we have measured is not very different from the whole body copper half-time estimates of 17, 26 and 29days, determined using whole-body counting of radioactive copper [16-181, suggesting that the copper on plasma caeruloplasmin is returned to the liver for excretion via the biliary system which is a major excretory pathway. The longer biological half-time for 65Cu in the plasma of heterozygotes for the WD gene may be related to variations in the enzyme activity or level of synthesis of the hepatic form of the postulated copper-transporting ATPase caused by the WD mutations on one gene.
The oral administration of 3mg of stable 65Cu produces a sufficiently large change in the isotopic composition of the plasma copper pool to allow the fate of the absorbed dose to be followed by 1CP:MS. The shape of the enrichment profiles for healthy control subjects, heterozygotes and WD patients was found to be similar to those obtained using radioactive copper.
